Home/Filings/4/0001439222-25-000011
4//SEC Filing

Washburn Theodore James Jr. 4

Accession 0001439222-25-000011

CIK 0001439222other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 4:06 PM ET

Size

24.4 KB

Accession

0001439222-25-000011

Insider Transaction Report

Form 4
Period: 2025-03-01
Washburn Theodore James Jr.
Principal Accounting Officer
Transactions
  • Sale

    Common stock

    2025-03-03$35.54/sh697$24,7717,691 total
  • Sale

    Common stock

    2025-03-03$35.54/sh727$25,8389,414 total
  • Award

    Restricted stock units

    2025-03-01+8,0858,085 total
    Common stock (8,085 underlying)
  • Exercise/Conversion

    Restricted stock units

    2025-03-017770 total
    Common stock (777 underlying)
  • Exercise/Conversion

    Common stock

    2025-03-01+7776,269 total
  • Exercise/Conversion

    Common stock

    2025-03-01+2,3508,388 total
  • Exercise/Conversion

    Restricted stock units

    2025-03-012,3502,350 total
    Common stock (2,350 underlying)
  • Sale

    Common stock

    2025-03-03$35.54/sh231$8,2106,038 total
  • Exercise/Conversion

    Common stock

    2025-03-01+2,45010,141 total
  • Award

    Restricted stock units

    2025-03-01+6,1426,142 total
    Common stock (6,142 underlying)
  • Exercise/Conversion

    Restricted stock units

    2025-03-032,4504,900 total
    Common stock (2,450 underlying)
Footnotes (10)
  • [F1]Includes 55 shares purchased through the Company's employee stock purchase plan.
  • [F10]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F2]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022.
  • [F3]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
  • [F4]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
  • [F5]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F6]The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F7]The restricted stock units were granted on March 1, 2025. On February 1, 2027, the shares underlying the restricted stock units will vest in full.
  • [F8]The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F9]The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001874199

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:06 PM ET
Size
24.4 KB